Disclaimer

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Tag

Non-regulated
Seasoned medtech leader with more than 30 years’ healthcare experience Ghent, Belgium – 25 August 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces the appointment of Alexandra Clyde as an independent Non-Executive...
Read More
Highly experienced US medtech leader brings more than 40 years’ experience Ghent, Belgium – 19 July 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, today announces the appointment of Doug Kohrs as an independent Non-Executive...
Read More
Ghent, Belgium – 8 April 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that it will attend the following upcoming investor conferences in April 2022: 21st Annual Needham Healthcare Conference, Virtual,...
Read More
Reporting of primary endpoint on track for Q4 2022 FDA regulatory submission on track for mid-2023 70% survival of POSEIDON Roll-In patients at one year post-implantation1 compares favourably to published literature in this high-risk patient population Ghent, Belgium – 5 April 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), an...
Read More
  Ghent, Belgium – 31 March 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, will announce its full year results ended 31 December 2021 on Tuesday, 12 April 2022. The management team will...
Read More
Ghent, Belgium – 09 March 2022 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that Ian Crosbie, Chief Executive Officer, will present at the following upcoming investor conferences in March 2022: BioCapital...
Read More
alfapump® is one of the first novel Class III active implantable medical devices to be certified Ghent, Belgium – 14 February 2022 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces it has...
Read More
Ghent, Belgium – 3 February 2022 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that Ian Crosbie, Chief Executive Officer, will present at BTIG’s Medtech, Digital Health, Life Science and Diagnostic Tools...
Read More
CEO Ian Crosbie to participate in a panel discussion on “MedTech and digital tools: What is the Mindset for 2022?” Ghent, Belgium – 17 December 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure,...
Read More
Positive interim analysis reported in July 2021 Reporting of primary endpoint planned for Q4 2022 Ghent, Belgium – 6 December 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces the completion of...
Read More
1 2 3 4 5 9

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES